These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29422321)

  • 1. Broad variability in pharmacokinetics of GH following rhGH injections in children.
    Lundberg E; Andersson B; Kriström B; Rosberg S; Albertsson-Wikland K
    Growth Horm IGF Res; 2018 Jun; 40():61-68. PubMed ID: 29422321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A; Wu Z; Kratzsch J; Keller E; Blum WF; Kniess A; Preiss R; Teichert J; Strasburger CJ; Bidlingmaier M
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian variation in the pharmacokinetics of steady state continuous subcutaneous infusion of growth hormone in adult growth hormone deficient patients.
    Janukonyté J; Parkner T; Lauritzen T; Christiansen JS; Laursen T
    Growth Horm IGF Res; 2013 Dec; 23(6):256-60. PubMed ID: 24094495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and chronic effects of subcutaneous growth hormone (GH) injections on plasma levels of GH binding protein in short children.
    Bjarnason R; Albertsson-Wikland K; Carlsson LM
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2756-60. PubMed ID: 7673420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
    Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children.
    Schena L; Meazza C; Pagani S; Paganelli V; Bozzola E; Tinelli C; Buzi F; Bozzola M
    J Pediatr Endocrinol Metab; 2017 Feb; 30(2):197-201. PubMed ID: 28099132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
    Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased GH dose after the catch-up growth period maintains metabolic outcome in short prepubertal children with and without classic GH deficiency.
    Decker R; Albertsson-Wikland K; Kriström B; Halldin M; Dahlgren J
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):407-15. PubMed ID: 22417085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
    Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
    Kriström B; Aronson AS; Dahlgren J; Gustafsson J; Halldin M; Ivarsson SA; Nilsson NO; Svensson J; Tuvemo T; Albertsson-Wikland K
    J Clin Endocrinol Metab; 2009 Feb; 94(2):483-90. PubMed ID: 19001519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of moderate interval exercise versus supine rest on the pharmacokinetics and pharmacodynamic profiles of subcutaneously administered growth hormone in adult growth hormone deficient patients.
    Janukonytė J; Parkner T; Lauritzen T; Christiansen JS; Frystyk J; Pedersen HS; Laursen T
    Growth Horm IGF Res; 2014 Oct; 24(5):198-204. PubMed ID: 25037883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
    Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.
    Grumbach MM; Bin-Abbas BS; Kaplan SL
    Horm Res; 1998; 49 Suppl 2():41-57. PubMed ID: 9730672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone deficiency: new approaches to the diagnosis.
    Binder G
    Pediatr Endocrinol Rev; 2011 Sep; 9 Suppl 1():535-7. PubMed ID: 22423512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone.
    Gilfoyle D; Mortensen E; Christoffersen ED; Leff JA; Beckert M
    Growth Horm IGF Res; 2018 Apr; 39():34-39. PubMed ID: 29273485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children.
    Bozzola M; Radetti G; Pagani S; Draghi M; Aimaretti G; Rondini G
    J Endocrinol Invest; 1999 Nov; 22(10):790-5. PubMed ID: 10614529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in serum GH cut-off values for pharmacological tests of GH secretion depend on the serum GH method. Clinical validation from the growth velocity score during the first year of treatment.
    Chaler EA; Rivarola MA; Guerci B; Ciaccio M; Costanzo M; Travaglino P; Maceiras M; Pagani S; Meazza C; Bozzola E; Barberi S; Bozzola M; Belgorosky A
    Horm Res; 2006; 66(5):231-5. PubMed ID: 16912509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.